Sanofi Buys Synthorx
Sanofi buys Synthorx.
Sanofi buys Synthorx to boost its immuno-oncology conduit for $2.5 billion.
Synthorx is a clinical-stage biotech firm focused on extending and improving the lives of people with cancer and autoimmune disorders. Synthorx’s proprietary Expanded Genetic Alphabet platform opens out the genetic code by adding a new DNA base pair. It's designed to create optimized biologics called Synthorins. A Synthorin is a protein enhanced by integrating fresh amino acids encoded by the new DNA base pair. This makes possible site-specific changes, which boost the pharmacological properties of these therapeutics.
The Expanded Genetic Alphabet platform will be used to develop a distinctive therapeutic conduit. Alone, and combined with other existing Sanofi platforms, it will support the development of a broad range of new biologics, such as drug conjugates, protein fusions, and multi-specific biologics. These medicines stretch out way beyond oncology to other beneficial areas.
Paul Hudson of Sanofi said: ‘This acquisition fits perfectly with our strategy to build a portfolio of high-quality assets and to lead with innovation. Also, it's aligned with our goal to build our oncology franchise with potentially practice-changing medicines and novel combinations.’
John Reed of Sanofi said: ‘Synthorx’s exceptionally novel discovery platform has already produced a molecule that has the potential to become a foundation of the next generation of immuno-oncology combination therapies. By selectively expanding the numbers of effector T-cells and natural killer cells in the body, THOR-707 can be combined with our current oncology medicines and our emerging pipeline of immuno-modulatory agents for treating cancer. Moreover, Synthorx’s pipeline of engineered lymphokines has great promise not only for oncology but also for addressing many autoimmune and inflammatory diseases.’
Laura Shawver of Synthorx said: ‘We are grateful that Sanofi has acknowledged the value of our Expanded Genetic Alphabet platform and the potential of our pipeline of optimized therapeutics for cancer and autoimmune disorders. Importantly, Sanofi has a portfolio of therapeutics that holds incredible promise for combining with our cytokine Synthorins to benefit patients around the world. I want to thank our employees and the Sanofi organization for their relentless efforts on behalf of patients.’
Morgan Stanley served as financial advisor to Sanofi. Weil, Gotshal & Manges served as legal advisor.
Centerview Partners served as financial advisor to Synthorx. Cooley served as legal advisor.
Sanofi buys Synthorx to boost its immuno-oncology conduit for $2.5 billion.
Synthorx is a clinical-stage biotech firm focused on extending and improving the lives of people with cancer and autoimmune disorders. Synthorx’s proprietary Expanded Genetic Alphabet platform opens out the genetic code by adding a new DNA base pair. It's designed to create optimized biologics called Synthorins. A Synthorin is a protein enhanced by integrating fresh amino acids encoded by the new DNA base pair. This makes possible site-specific changes, which boost the pharmacological properties of these therapeutics.
The Expanded Genetic Alphabet platform will be used to develop a distinctive therapeutic conduit. Alone, and combined with other existing Sanofi platforms, it will support the development of a broad range of new biologics, such as drug conjugates, protein fusions, and multi-specific biologics. These medicines stretch out way beyond oncology to other beneficial areas.
Paul Hudson of Sanofi said: ‘This acquisition fits perfectly with our strategy to build a portfolio of high-quality assets and to lead with innovation. Also, it's aligned with our goal to build our oncology franchise with potentially practice-changing medicines and novel combinations.’
John Reed of Sanofi said: ‘Synthorx’s exceptionally novel discovery platform has already produced a molecule that has the potential to become a foundation of the next generation of immuno-oncology combination therapies. By selectively expanding the numbers of effector T-cells and natural killer cells in the body, THOR-707 can be combined with our current oncology medicines and our emerging pipeline of immuno-modulatory agents for treating cancer. Moreover, Synthorx’s pipeline of engineered lymphokines has great promise not only for oncology but also for addressing many autoimmune and inflammatory diseases.’
Laura Shawver of Synthorx said: ‘We are grateful that Sanofi has acknowledged the value of our Expanded Genetic Alphabet platform and the potential of our pipeline of optimized therapeutics for cancer and autoimmune disorders. Importantly, Sanofi has a portfolio of therapeutics that holds incredible promise for combining with our cytokine Synthorins to benefit patients around the world. I want to thank our employees and the Sanofi organization for their relentless efforts on behalf of patients.’
Morgan Stanley served as financial advisor to Sanofi. Weil, Gotshal & Manges served as legal advisor.
Centerview Partners served as financial advisor to Synthorx. Cooley served as legal advisor.
Comments
Post a Comment